From December 2008 to February 2010 , 92 prostate cancer patients scheduled for intensity-modulated radiotherapy ( 77 Gy in 35 fractions ) using fiducial marker-based position verification were randomly assigned to receive magnesium oxide ( 500 mg twice a day ) or placebo during radiotherapy .